| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-06 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-06 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.15 | 7e-06 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-05 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-05 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-05 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.13 | 5e-05 |